BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30265706)

  • 1. Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot study.
    Wegermann K; Henao R; Diehl AM; Murphy SK; Abdelmalek MF; Moylan CA
    PLoS One; 2018; 13(9):e0204308. PubMed ID: 30265706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease.
    Murphy SK; Yang H; Moylan CA; Pang H; Dellinger A; Abdelmalek MF; Garrett ME; Ashley-Koch A; Suzuki A; Tillmann HL; Hauser MA; Diehl AM
    Gastroenterology; 2013 Nov; 145(5):1076-87. PubMed ID: 23916847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, SAMM50, and PARVB of patients with non-alcoholic fatty liver disease.
    Kitamoto T; Kitamoto A; Ogawa Y; Honda Y; Imajo K; Saito S; Yoneda M; Nakamura T; Nakajima A; Hotta K
    J Hepatol; 2015 Aug; 63(2):494-502. PubMed ID: 25776890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
    J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentially methylated loci in NAFLD cirrhosis are associated with key signaling pathways.
    Gerhard GS; Malenica I; Llaci L; Chu X; Petrick AT; Still CD; DiStefano JK
    Clin Epigenetics; 2018 Jul; 10(1):93. PubMed ID: 30005700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A targeted analysis reveals relevant shifts in the methylation and transcription of genes responsible for bile acid homeostasis and drug metabolism in non-alcoholic fatty liver disease.
    Schiöth HB; Boström A; Murphy SK; Erhart W; Hampe J; Moylan C; Mwinyi J
    BMC Genomics; 2016 Jun; 17():462. PubMed ID: 27301979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease.
    Hardy T; Zeybel M; Day CP; Dipper C; Masson S; McPherson S; Henderson E; Tiniakos D; White S; French J; Mann DA; Anstee QM; Mann J
    Gut; 2017 Jul; 66(7):1321-1328. PubMed ID: 27002005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis.
    Leti F; Malenica I; Doshi M; Courtright A; Van Keuren-Jensen K; Legendre C; Still CD; Gerhard GS; DiStefano JK
    Transl Res; 2015 Sep; 166(3):304-14. PubMed ID: 26001595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unique features associated with hepatic oxidative DNA damage and DNA methylation in non-alcoholic fatty liver disease.
    Nishida N; Yada N; Hagiwara S; Sakurai T; Kitano M; Kudo M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1646-53. PubMed ID: 26875698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism.
    Wang ZQ; Faddaoui A; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Guillemette C; Gobeil S; Macdonald E; Vanderhyden B; Bachvarov D
    Oncotarget; 2015 Oct; 6(31):31522-43. PubMed ID: 26372729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NAFLD is associated with methylation shifts with relevance for the expression of genes involved in lipoprotein particle composition.
    Mwinyi J; Boström AE; Pisanu C; Murphy SK; Erhart W; Schafmayer C; Hampe J; Moylan C; Schiöth HB
    Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Mar; 1862(3):314-323. PubMed ID: 27993651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide analysis of DNA methylation in human peripheral leukocytes identifies potential biomarkers of nonalcoholic fatty liver disease.
    Zhang RN; Pan Q; Zheng RD; Mi YQ; Shen F; Zhou D; Chen GY; Zhu CY; Fan JG
    Int J Mol Med; 2018 Jul; 42(1):443-452. PubMed ID: 29568887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction: Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot study.
    PLOS ONE Staff
    PLoS One; 2019; 14(2):e0212144. PubMed ID: 30721255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic and serum branched-chain fatty acid profile in patients with nonalcoholic fatty liver disease: A case-control study.
    Martínez-Montoro JI; Núñez-Sánchez MÁ; Martinez-Sanchez MA; Balaguer-Román A; Fernández-Ruiz VE; Ferrer-Gómez M; Sledzinski T; Frutos MD; Fernández-García JC; Mika A; Ramos-Molina B
    Obesity (Silver Spring); 2023 Apr; 31(4):1064-1074. PubMed ID: 36876627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative diagnostic accuracy of red cell distribution width-to-platelet ratio versus noninvasive fibrosis scores for the diagnosis of liver fibrosis in biopsy-proven nonalcoholic fatty liver disease.
    Cengiz M; Ozenirler S
    Eur J Gastroenterol Hepatol; 2015 Nov; 27(11):1293-9. PubMed ID: 26302023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetics in non-alcoholic fatty liver disease.
    Lee J; Kim Y; Friso S; Choi SW
    Mol Aspects Med; 2017 Apr; 54():78-88. PubMed ID: 27889327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Branched-chain amino acid transaminase 1 (BCAT1) promotes the growth of breast cancer cells through improving mTOR-mediated mitochondrial biogenesis and function.
    Zhang L; Han J
    Biochem Biophys Res Commun; 2017 Apr; 486(2):224-231. PubMed ID: 28235484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-1-Antitrypsin Pi*MZ variant increases risk of developing hepatic events in nonalcoholic fatty liver disease patients
    Murali AR; Prakash S; Sanchez AJ
    Clin Res Hepatol Gastroenterol; 2023 Feb; 47(2):102066. PubMed ID: 36509354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Petta S; Valenti L; Svegliati-Baroni G; Ruscica M; Pipitone RM; Dongiovanni P; Rychlicki C; Ferri N; Cammà C; Fracanzani AL; Pierantonelli I; Di Marco V; Meroni M; Giordano D; Grimaudo S; Maggioni M; Cabibi D; Fargion S; Craxì A
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2660-2669. PubMed ID: 28472477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphatase and tensin homolog is a differential diagnostic marker between nonalcoholic and alcoholic fatty liver disease.
    Sanchez-Pareja A; Clément S; Peyrou M; Spahr L; Negro F; Rubbia-Brandt L; Foti M
    World J Gastroenterol; 2016 Apr; 22(14):3735-45. PubMed ID: 27076758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.